| 2026-12-01 | retatrutide | Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis Carneiro GRA, da Costa Nunes IK, Dos Santos Cardoso GR, Dos Santos PF, Padilha MC, Nogueira FCS, Pereira HMG. | Rapid Commun Mass Spectrom |
| 2026-12-01 | semaglutide | EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted TherapyEuropean Association for the Study of the Liver (EASL). Electronic address: [email protected], European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). | J Hepatol |
| 2026-12-01 | tirzepatide | Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort Manueli Laos EG, Fontaine-Nicola A, Serafica B, Zhang L, Layden BT, Berger R, Orda CA, Schlottmann F, Pirzada A, Masrur MA. | Clin Obes |
| 2026-11-01 | tirzepatide | Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort Rescalli MB, Fagiolini A, Carmellini P, Pinzi M, Castaldo F, Cuomo A. | Hum Psychopharmacol |
| 2026-10-09 | semaglutide | Comment on 'Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data' Choudhry MA. | Br J Clin Pharmacol |
| 2026-10-09 | tirzepatide | Tirzepatide persistence, adherence, and dose escalation in a real-world setting with high out-of-pocket costs: a Polish cohort study Dziewierz A, Krawczyk-Ożóg A, Szarpak Ł, Kowalska-Bobko I, Siudak Z. | Adv Med Sci |
| 2026-10-09 | retatrutide | Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain Rubin R. | JAMA |
| 2026-10-08 | semaglutide | Ischemic colitis associated with oral semaglutide with recurrence upon rechallenge Aranda Rojas S, Chen Wang Y, Tavío Hernández E, Parejo Carbonell S, Romío de Las Heras E, Albillos Martínez A. | Rev Esp Enferm Dig |
| 2026-10-08 | tirzepatide | Tirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signaling He Y, Ma T, Xing H, Cao X, Song F, Pan Y, Ren L. | Eur J Pharmacol |
| 2026-10-08 | semaglutide | The impact of semaglutide initiated six months after laparoscopic sleeve gastrectomy on long-term weight loss and metabolic outcomes: single-center preliminary study Jeske P, Roleder J, Zastawna K, Krokowicz Ł, Szmyt K. | Surg Endosc |
| 2026-10-07 | retatrutide | Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide Buzzi RM, Huber LC. | BMJ Case Rep |
| 2026-10-07 | tirzepatide | Re: Hong et al.: Ocular Outcomes with Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes (Ophthalmol Retina. 2026;10:625-632) Guang X, Zhang G, Wang Y, Chai H. | Ophthalmol Retina |
| 2026-10-07 | semaglutide | The Conventional Cost-Effectiveness and Distributional Cost-Effectiveness of Semaglutide for Obesity Treatment Kulkarni NS, Hutton D, Rhyan C, McCullough JS, Greenlee M, Pandya A. | Obesity (Silver Spring) |
| 2026-10-07 | tirzepatide | Kidney Outcomes With GLP-1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real-World Cohort Study Sehtman-Shachar DR, Fishkin A, Leibowitz G, Mosenzon O, Schechter M, Aharon-Hananel G. | Diabetes Obes Metab |
| 2026-10-06 | tirzepatide | Annals On Call - Tirzepatide Versus Intensified Conventional Care for Poorly Controlled Type 2 Diabetes Centor RM, Batch BC. | Ann Intern Med |
| 2026-10-06 | danuglipron | Danuglipron and orforglipron engage GLP-1R through materially different interfaces: an unbiased molecular dynamics study Oztekin A, Turker S. | bioRxiv preprint |
| 2026-10-05 | semaglutide | Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes Al-Nusair M, Khurana S, Eysha M, Elchouemi M, Zaki IH. | J Diabetes Metab Disord |
| 2026-10-02 | tirzepatide | Tirzepatide attenuates cardiac microvascular injury and ferroptosis-related lipid peroxidation in diabetic mice: endothelial responses in the context of partial PRKN silencing Lu G, Wang X, Zhuang H, Wang X, Zhou X, Zhao G. | Eur J Pharmacol |
| 2026-10-02 | survodutide | Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties Sergi CM. | Contemp Clin Trials |
| 2026-10-01 | semaglutide | Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease Gong C, Luo Q, Li Q. | Medicine (Baltimore) |
| 2026-10-01 | exenatide | Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial Gurney R, Girges C, Vijiaratnam N, Athauda D, Gandhi S, Morris H, Foltynie T. | Brain |
| 2026-10-01 | survodutide | Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease Hamilton A, Thisted L, Ougaard M, Hahn M, Andersen K, Perens J, Augustin R, Bajrami B, Rist W, Christensen M, Hansen HH, Klein T. | Diabetes Obes Metab |
| 2026-10-01 | retatrutide | Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2? Holst JJ. | Lancet |
| 2026-10-01 | tirzepatide | Real-world treatment patterns and cost per patient achieving treatment targets among tirzepatide and semaglutide initiators in US patients with type 2 diabetes Hoog MM, Vallarino C, Maldonado JM, Grabner M, Teng CC, Terrell K, Richard EL. | J Manag Care Spec Pharm |
| 2026-10-01 | semaglutide | Early Adoption and Diffusion of Oral Semaglutide in US Adults With Obesity Lei Y, Tang H, Jian X, Asch DA, Chen Y. | JAMA Netw Open |
| 2026-10-01 | tirzepatide | Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues Popa Ilie IR, Ghibu S, Butuca A, Dobrea CM, Frum A, Stoicescu L, Homorodean C, Gligor FG, Morgovan C. | BMJ Open |
| 2026-10-01 | survodutide | Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes Wharton S, le Roux CW, Startseva E, Kloer IM, Alhussein A, Hussain SA, Unseld A, Bozkurt B, Ard JD, Bays HE, Bogdański P, Butt JH, Ekinci EI, Jastreboff AM, Ji L, Schou M, Tinahones FJ, Kokkinos AD, Merkely B, Ogawa W, Pedersen SD, Pietiläinen KH, Quinn D, Sattar N, Seufert J, Stenlöf K, van Beek AP, Vangoitsenhoven R, Brueckmann M, Younes R, Kaplan LM, SYNCHRONIZE-2 Investigators. | N Engl J Med |
| 2026-10-01 | retatrutide | Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest Wise J. | BMJ |
| 2026-10-01 | exenatide | Reply: Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial Woo KA, Jang Y, Kim HJ, Park PJ. | Brain |
| 2026-10-01 | tirzepatide | Personalising maintenance after tirzepatide weight loss van Bruggen FH, Damhof MA. | Lancet |
| 2026-10-01 | tirzepatide | In brief: A cardiovascular indication for tirzepatide (Mounjaro) | Med Lett Drugs Ther |
| 2026-09-30 | orforglipron | Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial Klein KR, Wysham C, Tuttle KR, Davies MJ, Cox D, Chen J, Wu WS, Denning M, Liu R, Ludwig L, Meskimen ER. | Lancet |
| 2026-09-29 | retatrutide | Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, Eyde S, Park SY, Ferro J, Johnson C, Taylor A. | Lancet |
| 2026-09-29 | petrelintide | Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial Garvey WT, Ard J, Connery L, Frias JP, le Roux CW, Pietiläinen KH, Dinesen M, Hagen BF, Larsen L, Hesse D, Kendall DM. | Lancet Diabetes Endocrinol |
| 2026-09-29 | retatrutide | Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, Ahmad NN, Murray M, Du Y, Makarova N, Giblin K, Schloot NC, Wang Y, TRIUMPH-1 Investigators. | N Engl J Med |
| 2026-09-29 | petrelintide | Petrelintide and the evolving role of amylin agonism in obesity Madsbad S, Holst JJ. | Lancet Diabetes Endocrinol |
| 2026-09-24 | exenatide | Mechanistic insights into the inhibition of insulin amyloidogenesis and associated toxicity by the p.M14L variant of exenatide Bahrami Z, Shalgahi MR, Shahsavani MB, Mirzaei Z, Zarei I, Amanlou M, Farjadian F, Moosavi-Movahedi AA, Yousefi R. | FEBS J |
| 2026-09-23 | semaglutide | Delays in access to generic semaglutide point to key missing pieces in Canada's drug approval system Eisenkraft Klein D, Kesselheim AS. | Health Policy |
| 2026-09-22 | liraglutide | Real-world cardiovascular effects of liraglutide: transportability analysis of the LEADER trial Josey K, Liu W, Warsavage T, Medici M, Kvist K, Derington CG, Reusch JEB, Ghosh D, Raghavan S. | Am J Epidemiol |
| 2026-09-22 | semaglutide | Sociodemographic disparities in semaglutide and tirzepatide prescription for obesity treatment Le MT, Stokes AC. | Health Aff Sch |
| 2026-09-20 | danuglipron | Efficacy and Safety of Oral Small-Molecule (Non-Peptide) GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity: A Systematic Review of the Complete Orforglipron and Danuglipron Clinical Development Programs Labate AM, Villari P, Cimino E, Giacomelli L, Oladeji OA, Agosti B. | Preprints.org preprint |
| 2026-09-19 | liraglutide | Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic Syndrome Ravić MP, Srejović IM, Andjić MM, Murić MD, Sretenović JZ, Jeremić NS, Milosavljević IM, Vuletić ML, Murić NN, Ravić KR, Bolevich SB, Sergeeva SP, Gorbunov AA, Bolevich SS, Jakovljević VL, Novaković JN. | Med Sci (Basel) |
| 2026-09-18 | tirzepatide | Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes Aronne LJ, Vincent RP, Klein KR, Brumm JF, Jouravskaya I, Cao D, Dimitriadis GK, Dunn JP. | Obes Pillars |
| 2026-09-18 | exenatide | Development of chondroitin sulfate‑stabilized PLGA microspheres of exenatide via polarity gradient extraction Khopade AJ, Halder A, Patel V, Joshi M, Burade V. | Pharm Dev Technol |
| 2026-09-18 | orforglipron | Orforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment Wietholter JP, Terpening CM. | Ann Pharmacother |
| 2026-09-17 | tirzepatide | Simultaneous and recurrent hordeola and chalazia associated with tirzepatide therapy: a case series Kolker A. | JCEM Case Rep |
| 2026-09-17 | orforglipron | Predicting the Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial Shinde S, Kahles F, Vasileva-Metodiev S, Griffin R, Liu-Seifert H, Lebrec J, Xavier NA, Li R, Klise SR, Singh A, Aberle J. | Diabetes Obes Metab |
| 2026-09-17 | dulaglutide | Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial Stewart KD, Matza LS, Chinthammit C, Pavo I, Bartee AK, Boye KS. | Diabetes Ther |
| 2026-09-15 | liraglutide | A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan Chiu CF, Chou CK, Hu SW, Huang KC, Wu YL, Wu HF, Liu YL, Yang YC, Chen HL, Yeung CY. | Obes Res Clin Pract |
| 2026-09-15 | orforglipron | Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis Hegaz MG, Aboud MYA, Kamel AII, Naveed MA, Elsayed OG, Sorathia AZ. | BMC Endocr Disord |
| 2026-09-15 | liraglutide | Sequential liraglutide and setmelanotide therapy in Bardet-Biedl Syndrome: metabolic and renal outcomes in a real-world case report and literature review Pasquariello T, Secondulfo F, Roscini AR, Nardi E, Prosperi E, Capasso G, Perna AF, Zacchia M. | Nephron |
| 2026-09-15 | retatrutide | Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats Petersen J, Merrild C, Holm SK, Kurgan N, Hassan S, Mathiesen CV, Börchers S, Svendsen C, D'Anna S, Andersen NR, Klein AB, Fritzen AM, Deshmukh AS, Pers TH, Clemmensen C. | Nat Metab |
| 2026-09-11 | ecnoglutide | Dose-response and time-course effects of ecnoglutide in type 2 diabetes: a systematic review and meta-analysis of efficacy Feng Y, Sun C, Li X, Hu L, Zhou K, Li L, Yuan Y, Yu L, Wu M, Liu L. | Front Endocrinol (Lausanne) |
| 2026-09-10 | tirzepatide | Increased energy expenditure through intermittent cold exposure does not enhance tirzepatide-induced weight loss in obese mice Bellucci A, Alfares H, Gale C, Akcan M, Waters B, Eisner K, Baranowski BJ, Jeromson S, Babicki-Moore A, Wright DC. | Am J Physiol Regul Integr Comp Physiol |
| 2026-09-09 | tirzepatide | Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study Rivera Gutierrez RJ, Castaneda R, Verastegui A, Ghusn W, Bechenati D, Espinosa MA, Villamarin J, Tama E, Frederiksen K, Acosta A, Hurtado Andrade MD. | J Endocr Soc |
| 2026-09-09 | orforglipron | Orforglipron and the Kidney: A Promise or Disappointment? The Need for Trials Examining Renal Outcomes Shah J, Luna Ceron E, Payan-Schober F, Hechanova LA, Clegg DJ, Palmer BF. | Am J Nephrol |
| 2026-09-08 | orforglipron | Keeping the weight off: can oral orforglipron maintain all the weight loss following glucagon-like peptide-1 receptor agonist (GLP-1 RA) discontinuation? Alhazmi A, le Roux CW. | Expert Rev Clin Pharmacol |
| 2026-09-08 | liraglutide | Liraglutide Ameliorates Atrial Fibrillation in Association with Enhanced Adiponectin Signaling in Epicardial Adipose Tissue Li X, Liu Y, Wang F, Zhang F, Zhang L, Dang Y, Qi X. | Cardiovasc Drugs Ther |
| 2026-09-04 | liraglutide | Liraglutide Attenuates Hepatocyte Ferroptosis in an In Vitro Model of Metabolic Dysfunction-Associated Steatotic Liver Disease Bai J, Xiao Y, Lou P, Zhang J, Liu Y, Zhou Y. | Physiol Res |
| 2026-09-04 | liraglutide | Comparative Efficacy and Safety of Liraglutide Versus Metformin in Women With Polyendocrine Metabolic Ovarian Syndrome (PMOS): A Systematic Review and Meta-Analysis of Randomized Controlled Trials Banerjee I, Krissheeven M, Pandey N, Banerjee S, Robinson J, Banerjee I. | Cureus |
| 2026-09-04 | liraglutide | Safety and Glycemic Efficacy of Perioperative Liraglutide in Cardiac Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Gamal I, Elkasaby MH, Ewidat O, Riyad N, Sadin Z, Singh Gill A, Nassar M, Frishman WH, Aronow WS. | Cardiol Rev |
| 2026-09-03 | liraglutide | An Orthogonal Framework for Higher-Order Structural and In Vitro Functional Comparability of Chemically Synthesized Liraglutide Relative to an rDNA-Origin Reference Product Tang Y, Bai M, Lu X, Xing X. | Pharm Res |
| 2026-09-01 | liraglutide | Weight Loss-Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide Al Ozairi E, Irshad M, Alkandri J, Mashankar A, Gray SR, le Roux CW. | Diabetes Metab Res Rev |
| 2026-09-01 | liraglutide | Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review Bawadi H, Abuhijleh H, Nofal M, Zakaria ZZ, Al-Asmakh M. | Endocrinol Diabetes Metab |
| 2026-09-01 | liraglutide | A Novel Dual Therapy for Diabetic Ischemic Heart Injury: Sinomenine and Liraglutide Restore Mitochondrial Homeostasis and Suppress Pyroptosis Duan B, Han R. | FASEB J |
| 2026-09-01 | dulaglutide | Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical Trials Hageen AW, Gadelmawla AF, Saleh AO, Bahnasy S, Eladawi S, Abdelaziz M, Iyad K, Kandil AH, Zinhom K, Mohamed MR, Abdulhay H, Turkman M, Abdelazeem B, Fonarow GC. | Endocrinol Diabetes Metab |
| 2026-09-01 | liraglutide | Study on the Regulatory Mechanism of GLP-1 Receptor Agonist Liraglutide in Diabetic Corneal Epithelial Wound Healing Liu X, Lin H, Shao Y, Shen J, Bi Y. | Invest Ophthalmol Vis Sci |
| 2026-09-01 | retatrutide | Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia Piatkowski T, Craven A, Cornell S, Ferris J. | Drug Alcohol Rev |
| 2026-09-01 | liraglutide | Liraglutide in Adults With Obesity: A Multicentre, Single-Arm, Post-Marketing Surveillance Study in Taiwan Tu ST, Chiu CF, Chou CK, Chuang HH, Hu SW, Ko WC, Lee CY, Lin WY, Sung YJ, Tzeng TF, Wang W, Wu HF, Yeung CY, Chen B, Sim CJ, Huang KC. | Endocrinol Diabetes Metab |
| 2026-09-01 | liraglutide | Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy Xu X, Trigo-Mouriño P, Gao Q, Liang Y, McCoy MA, Reibarkh M. | Anal Chem |
| 2026-09-01 | dulaglutide | Comment on Ostrominski et al. Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations Zhang Y, Liu J. | Diabetes Care |
| 2026-08-31 | mazdutide | Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials Hassan A, Farooq QUA, Parwesh F, Rasul M, Masood A, Aftab H, Riaz H, Mahmood A, Malik MA, Rehman AU, Nenwani K, Ahmad MA, Basharat A, Rasul M, Sarwar A, Hasan AH. | F1000Res preprint |
| 2026-08-31 | retatrutide | Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework Kaczynski MM, Zureikat RM, Kaczynski MR, Sitarz R, Karakuła-Juchnowicz H. | Biomedicines |
| 2026-08-31 | semaglutide | Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study Montaser E, Bhasin K, Kruger D, Akturk HK, Ahmann A, Snell-Bergeon JK, Shah VN. | Diabetes Obes Metab |
| 2026-08-30 | semaglutide | Intrathecal semaglutide attenuates burn injury-induced pain in mice through a spinal GLP-1R-linked enkephalin/δ-opioid receptor pathway He Y, Gao J, Liu Y, Wu S, Kuang J, Chen D, Xu B, Zhang M, Fang Q. | Neuropharmacology |
| 2026-08-26 | retatrutide | Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis Branine N. | Cureus |
| 2026-08-26 | semaglutide | Analytical methods for the determination of semaglutide in pharmaceutical formulations and biological matrices: A comprehensive review Kavibharathi V, Thirusha KM, Vijayadevan G, Vijayakumar R, Nalini CN. | J Chromatogr B Analyt Technol Biomed Life Sci |
| 2026-08-25 | survodutide | Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial Kaplan LM, Startseva E, le Roux CW, Wharton S, Bozkurt B, Mazo DF, von Schlippenbach J, González Maldonado S, Ajaz Hussain S, Neff GW, Gonzalez Rojas Y, Smith C, Younes R, Sanyal AJ, SYNCHRONIZE-MASLD Investigators. | Nat Med |
| 2026-08-24 | semaglutide | Synthetic Versus Reference Semaglutide for Weight Management: Reporting Gaps and Clinical Claims Singh AK, Singh A, Singh R. | Diabetes Obes Metab |
| 2026-08-24 | tirzepatide | Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis Upadhyay N, Bonakdar A, Subedi K, Banerjee S, Behrend B, Hankosky ER. | Diabetes Obes Metab |
| 2026-08-21 | mazdutide | Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial Hsia SH, Bays HE, Billings LK, Weideman AMK, Mather KJ, Coskun T, Haupt A, Thomas MK, Tham LS, Calderon B, Ni W, De Araujo OFG. | Lancet Diabetes Endocrinol |
| 2026-08-19 | dulaglutide | Dulaglutide vs insulin in adolescents with thalassaemia-induced diabetes: effect on metabolism and atherogenesis (DIADEMA) Adly AAM, Ismail EAR, Abdel Kader MSEM, Sadeq MR, Salah NY. | Diabetologia |
| 2026-08-18 | semaglutide | Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide Rasmussen BS, Simonÿ C, Poulsen ML, Uhrenholt NG, Lundberg B, Rønne ST, Uhrenholt PG, Gæde PH, Arnfred SM. | Int J Qual Stud Health Well-being |
| 2026-08-17 | semaglutide | Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial Miyake T, Yoshida O, Furukawa S, Hirooka M, Abe M, Tokumoto Y, Kanamoto A, Watanabe T, Yano R, Okazaki Y, Yukimoto A, Nakamura Y, Takeshita E, Kumagi T, Hiasa Y. | Diabetes Obes Metab |
| 2026-08-17 | orforglipron | Safety and tolerability of orforglipron in Japanese people with type 2 diabetes Nauck MA, Horowitz M. | Lancet Diabetes Endocrinol |
| 2026-08-17 | retatrutide | Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes Ruotolo G, Harris C, Lin Y, Wilson JM, Pirro V, Duffin KL, Thomas MK, Hartman ML, Neill CO, Coskun T, Milicevic Z, Haupt A, Sattar N, Nicholls SJ. | Diabetes Obes Metab |
| 2026-08-17 | dulaglutide | Glucagon-like peptide-1 receptor agonist dulaglutide attenuates liver injury in metabolic dysfunction-associated steatotic liver disease with diabetic mice Wang Y, Hao D, Fan X, Pan L, Duan H, Yan J, Yao Y, Zha M, Sarun P, Du Y, Wang X, Zhong X, Pan T. | Eur J Pharmacol |
| 2026-08-17 | orforglipron | Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial Yabe D, Shiraiwa T, Ugai H, Takeuchi M, Suzuki R. | Lancet Diabetes Endocrinol |
| 2026-08-14 | survodutide | Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN) Ji L, Chen L, Cheng Z, Lu Y, Yang Y, Fu F, Zhu Y, Jin L, Kloer IM. | Diabetes Ther |
| 2026-08-13 | liraglutide | Liraglutide and Βeta-Cell Function in Young Adults With Long-Standing Type 1 Diabetes and Residual C-Peptide: A Blinded, Randomized Controlled Trial Caballero-Corbalán J, Lundkvist P, Espes D, Carlsson PO. | Diabetes Obes Metab |
| 2026-08-13 | retatrutide | Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice Ding M, Li X, Wei Y, Wang J, Jiao B, Li C, Ma W, Peng Y, Shen J, Yu G, Gao C. | iScience |
| 2026-08-11 | semaglutide | Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting Liu T, Ren X, Li Y, Wang J, Chen J, Lin R, Zhang J. | J Enzyme Inhib Med Chem |
| 2026-08-10 | semaglutide | Prescribed but Not Filled: Patient Factors Related to Semaglutide/Tirzepatide Prescription Fills Among Those With Prescription Orders for Obesity Treatment Acharya M, Thakur D. | Diabetes Obes Metab |
| 2026-08-10 | tirzepatide | Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6-Month Claims Database Analysis Gibble TH, Venkataraman M, Mojdami D, Vallarino C, Stockbower G, Grabner M, Ananth M, Desai K. | Diabetes Obes Metab |
| 2026-08-07 | retatrutide | Retatrutide: Obesity drug opens to "compassionate use" in US after speculation Trump took it Brown C. | BMJ |
| 2026-08-06 | semaglutide | Safety of semaglutide on depressive symptoms among people with HIV in routine clinical care Haidar L, Ruderman SA, Leong C, Doupe MB, Lesko C, Delaney JAC, Alba D, Drumright LN, Fojo AT, Fredericksen RJ, Hahn A, Heath SL, Hwang YJ, Karris M, Kitahata MM, Kyle RP, Mayer KH, Napravnik S, Pettit AC, Rodriguez A, Saag MS, Whitney BM, Yendewa G, Crane HM, Eltonsy S. | AIDS |
| 2026-08-06 | orforglipron | Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension Laffin L, Schlaich MP, Hall ME, Xie CC, Rao G, Rettiganti M, Dennehy EB, Linetzky B. | Am J Prev Cardiol |
| 2026-08-06 | liraglutide | Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis Pałka W, Moćko P, Śladowska K, Holko P, Kawalec P. | J Endocrinol Invest |
| 2026-08-05 | liraglutide | Oral Janus nanomotor covalent conjugation rapeseed protein-derived DPP-IV inhibitory peptide and liraglutide: A self-propelled targeted delivery system for promoting insulin secretion and glucose-lowering Dong H, He H, Xing H, Guo C, Wang Z, He R. | Food Res Int |
| 2026-08-04 | tirzepatide | Confluent and reticulated papillomatosis improvement with tirzepatide-associated weight loss: A case report Bindra H, Paquette G, Levin N. | JAAD Case Rep |
| 2026-08-04 | liraglutide | Liraglutide reprograms vascular smooth muscle cell metabolism to suppress extracellular matrix remodeling in diabetic atherosclerosis Zhu K, Liu H, He N, Wang H, Liu J, Zhang Q, Liu Z. | J Diabetes Investig |
| 2026-08-04 | mazdutide | Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary | JAMA |
| 2026-08-04 | orforglipron | Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: Research Summary | JAMA |
| 2026-08-03 | liraglutide | Effects of liraglutide on gut bacterial community dynamics Bull J, Durham PL, Mirza BS. | Microbiol Spectr |
| 2026-08-03 | liraglutide | Liraglutide affects mitochondrial function and histone acetylation through the NQO1/SIRT3 pathway in diabetic kidney disease Gao J, Lv X, Zhao P, Pan B, Liu J. | Mol Cell Biochem |
| 2026-08-03 | survodutide | Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH Noureddin M, Sanyal AJ, Bedossa P, Fraessdorf M, Schoelch C, Startseva E, Marshall SR, Marshall SR, Alhussein A, Neff GW, Lawitz EJ, Lawitz EJ, Bugianesi E, Anstee QM, Newsome PN, Ratziu V, Hosseini-Tabatabaei A, Schattenberg JM, Alkhouri N, Younes R. | Hepatology |
| 2026-08-01 | retatrutide | Retatrutide effects on diabetic rats' cognition Ferreira J. | Lab Anim (NY) |
| 2026-08-01 | orforglipron | Mazdutide and Orforglipron-New Evidence in Obesity and Diabetes Gadde KM, Talebloo J, Heymsfield SB. | JAMA |
| 2026-08-01 | mazdutide | Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial Gao L, Jiang H, Cai H, Tian J, Shi B, Qiu W, Huang C, Han J, Zhang S, Pang S, Bi Y, Chen L, Gu X, Han J, Ma Q, Deng H, Wang Y, Li L, Han-Zhang H, Qian L, Ji L, GLORY-2 Trial Investigators. | JAMA |
| 2026-08-01 | orforglipron | Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial Giorgino F, D'Souza S, Ludwig L, Kiyosue A, Ibriga H, Rha H, Denning M, Wu WS, Fernández Landó L, Tobian J. | JAMA |
| 2026-08-01 | dulaglutide | Superior Cardiorenal Protection With Tirzepatide Over Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Large-Scale Propensity Score-Matched Real-World Analysis Khalil I, Hossain MI, Akter MM, Wahid F, Khalid AA, Promi SA, Sayed MA, Rahman MT, Sarker P. | Clin Cardiol |
| 2026-08-01 | dulaglutide | Dulaglutide-associated body odor with dechallenge and rechallenge in a patient with type 2 diabetes Marusic S, Staresinic M, Berkovic MC. | Int J Clin Pharmacol Ther |
| 2026-08-01 | aleniglipron | Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial Rosenstock J, Lingvay I, Ryan D, Jastreboff AM, Kushner R, Acosta A, Blevins TC, Choi M, Holmes FL, Smith T, Connery L, Li Y, Liu MK, Barth A, Butcher J, Civitarese A, Yue H, Coll B, ACCESS Trial Investigators. | Nat Med |
| 2026-08-01 | semaglutide | Semaglutide ameliorates traumatic sepsis-induced cardiac injury by activating the March5-ACSL4 axis to suppress ferroptosis Sun B, Liu L, Zhang H, Wang X, Chen L, Shen Y, Liu H, Kang H, Zhou F. | Free Radic Biol Med |
| 2026-07-30 | dulaglutide | Differential Protective Actions of Dulaglutide and Dexamethasone in Methotrexate Induced Pulmonary Fibrosis: Relationship with AMPK and Beclin-1 Levels Maher OW, El-Sayed NM, El-Awady EE, El-Orabi NF, Radwan A. | Biomedicines |
| 2026-07-27 | orforglipron | Orforglipron alleviates aortic aneurysm and dissection via inhibiting WNT5A noncanonical signaling Deng Y, Guo Z, Yu L, Zhang J, Qian J, Wang J, Chen X, Xu Z, Wang D, Kong C. | Biochem Pharmacol |
| 2026-07-25 | liraglutide | Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications Katamine A, Oya J, Kondo Y, Hasegawa Y, Nakagami T. | J Diabetes Investig |
| 2026-07-24 | semaglutide | Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study Wei Y, Gong Y, Gong J, Zeng H, Zhong Z, Xiong Y, Li X. | J Obstet Gynaecol |
| 2026-07-23 | retatrutide | Retatrutide and the urinary tract infection signal: Is the answer hidden in timing? Koufakis T, Argyrakopoulou G, Kokkinos A, le Roux CW. | Eur J Intern Med |
| 2026-07-21 | orforglipron | Orforglipron, a Small-Molecule Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA), Has Neuroprotective and Anti-Inflammatory Effects Li Y, Glotfelty EJ, Parekh P, Batsaikhan B, Luo W, Jackson SN, Harvey BK, Greig NH. | Cells |